Latest news with #Kisqali
The Advertiser
2 days ago
- Health
- The Advertiser
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice. Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signalling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Business Insider
2 days ago
- Health
- Business Insider
Novartis announces data from new subgroup analysis of Phase III NATALEE trial
Novartis (NVS) is announcing data from a new subgroup analysis of the Phase III NATALEE trial evaluating the efficacy and safety of Kisqali plus endocrine therapy in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, EBC, at high risk of recurrence across age and menopausal status. The data will be presented at the 2025 American Society of Clinical Oncology, ASCO, Annual Meeting. Results at median follow-up of 44.2 months show that patients receiving Kisqali continued to see consistent reductions in risk of recurrence across all efficacy measures, regardless of age and menopausal status. In this one-year post-treatment analysis, pre-menopausal and younger patients, who often present with more aggressive disease characteristics, experienced greater reductions in risk of recurrence and fewer treatment discontinuations due to adverse events than post-menopausal patients. Results include: 33% reduction in relative risk of invasive disease observed in pre-menopausal early breast cancer patients receiving Kisqali in 1-year post-treatment analysis; Tolerability remained consistent, with fewer treatment discontinuations due to adverse events among pre-menopausal patients; Separate real-world analysis presented at ASCO demonstrates differences in treatment outcomes that underscore critical need to improve care for Black patients with EBC. Confident Investing Starts Here:
Yahoo
2 days ago
- Business
- Yahoo
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
West Australian
2 days ago
- Health
- West Australian
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
Perth Now
2 days ago
- Health
- Perth Now
Blood test-guided treatment cuts breast cancer risk
Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard therapies cut the risk of disease progression or death by half, a finding that could be practice changing, experts say. The results, presented at the American Society of Clinical Oncology meeting in Chicago, mark the first use of a blood test called a liquid biopsy to indicate the need for a change in treatment in women with a common form of breast cancer, even before tumour growth can be detected on imaging. The early switch approach in women with hormone receptor-positive, HER2-negative breast cancer resulted in a 56 per cent reduction in the risk of disease progression or death, said Dr Eleonora Teplinsky, an oncologist at Valley-Mount Sinai Comprehensive Cancer Care and an ASCO breast cancer expert. "When patients progress on scans, we're already behind," Teplinsky said at a media briefing. She said an early switch approach, before disease progression, allows doctors "to essentially stay ahead of the curve." Camizestrant is not yet FDA-approved, but Teplinsky said she believes the data will likely result in a new treatment paradigm. The trial involved 3256 patients with advanced hormone receptor-positive, HER2-negative breast cancer, the most common type in which hormones such as oestrogen fuel cancer growth. These cancers lack high levels of HER2, another cancer driver. Women in the trial had at least six months of treatment with aromatase inhibitors that block hormones fueling the cancer, as well as targeted drugs called CDK4/6 inhibitors such as Novartis' Kisqali, Pfizer's Ibrance or Eli Lilly's Verzenio, which block an enzyme that fuels cancer growth. About 40 per cent of patients treated with aromatase inhibitors develop mutations in the oestrogen receptor 1 gene called ESR1 mutations, a sign of early drug resistance. Camizestrant and similar drugs called selective oestrogen receptor degraders, or SERDS, block oestrogen receptor signaling in cancer cells. In the trial, researchers used blood tests to identify 315 patients with signs of early drug resistance and then randomly assigned them to either switch to camizestrant plus the CDK4/6 inhibitor or continue with standard treatment plus a placebo. The researchers found that it took 16 months for the disease to progress in women who got camizestrant, compared with 9.2 months in those who continued on standard therapy, a statistically significant difference in a measure known as progression-free survival. No new side effects were reported and few patients from either group dropped out due to side effects. "This is going to be very impactful for our patients," said Dr Hope Rugo, head of breast medical oncology at City of Hope in Duarte, California. The question, she said, is how do doctors incorporate the testing into clinical practice.
